SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 million, under the...
Read More Details
Finally We wish PressBee provided you with enough information of ( Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib )
Also on site :
- CNN Confession: Jake Tapper Admits Conservative Media Was Right About Biden’s Cognitive Decline
- Over 20 Palestinians, children included, killed in Israeli airstrikes in Gaza
- Dem Bulb: Scott Jennings Laughs that Failure of Fake Biden Town Hall Was Blamed on Bad Lighting